# Study of LP-184 in Patients With Advanced Solid Tumors

> **NCT05933265** · PHASE1,PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Lantern Pharma Inc.** · enrollment: 64 (actual)

## Conditions studied

- Advanced Solid Tumor
- Metastatic Solid Tumor
- GBM
- TNBC - Triple-Negative Breast Cancer
- NSCLC
- Pancreatic Adenocarcinoma
- DDR Gene Mutation

## Interventions

- **DRUG:** LP-184
- **DRUG:** Olaparib
- **DRUG:** Nivolumab & Ipilimumab

## Key facts

- **NCT ID:** NCT05933265
- **Lead sponsor:** Lantern Pharma Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2023-06-09
- **Primary completion:** 2026-07-28
- **Final completion:** 2026-07-28
- **Target enrollment:** 64 (ACTUAL)
- **Last updated:** 2026-05-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05933265

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05933265, "Study of LP-184 in Patients With Advanced Solid Tumors". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT05933265. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*